000220 — Yuyu Pharma Income Statement
0.000.00%
Last trade - 00:00- KR₩76bn
- KR₩80bn
- KR₩133bn
- 48
- 83
- 82
- 84
Annual income statement for Yuyu Pharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 98,120 | 115,655 | 138,881 | 137,210 | 133,147 |
| Cost of Revenue | |||||
| Gross Profit | 45,269 | 45,335 | 53,313 | 48,897 | 51,705 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 91,905 | 114,455 | 139,917 | 137,587 | 121,799 |
| Operating Profit | 6,215 | 1,200 | -1,036 | -377 | 11,348 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 3,711 | -383 | -3,810 | -5,442 | 9,985 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2,413 | -920 | -4,425 | -5,541 | 10,289 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 1,284 | -2,214 | -5,988 | -7,181 | 8,720 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 999 | -2,499 | -6,273 | -6,303 | 7,778 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 68.6 | -156 | -359 | -360 | 428 |
| Dividends per Share |